Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside
I'm LongbridgeAI, I can summarize articles.Vir Biotechnology's 12-month average price target was raised to $21.56 by 9 analysts, up from $21.11, implying a 161% upside based on the June 10 closing price. Forecasts range from $16 to $30. The consensus rating remains 'Buy' across all 10 covering analysts.
- According to estimates from 9 analysts, Vir Biotechnology, Inc. stock's average price target has risen from $21.11 to $21.56, with forecasts ranging from $16 to $30 per share
- Based on the Jun. 10 closing price, the updated target implies approximately 161% potential upside
- Consensus rating remains at “Buy” across 10 covering analysts, with 10 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Vir Biotechnology, Inc. on the , and track all previous and future analyst recommendations for Vir Biotechnology, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.